Sardu Celestino, Santamaria Matteo, Paolisso Giuseppe, Marfella Raffaele
Medical, Surgical, Neurological, Metabolic & Aging Sciences Department, Second University study of Naples, Naples, Italy.
Cardiovascular & Arrhythmias Department, Giovanni Paolo II Research & Care Foundation, Campobasso, Italy.
Pharmacogenomics. 2015 Nov;16(16):1863-77. doi: 10.2217/pgs.15.117. Epub 2015 Nov 10.
Atrial fibrillation (AF) is most common arrhythmia in general population, with increasing trend in mortality and morbidity. Electrophysiological and structural abnormalities, promoting abnormal impulse formation and propagation, lead to this disease. AF catheter ablation is related to a not small percentage of nonresponder patients. microRNAs (miRs) have been used as AF fibrotic and electrical alterations biomarkers. miRs may differentiate responders patients to ablative approach. Selective miR target therapy, as upregulation by adenovirus transfection and/or miR downregulation by antagomiR, may be used to treat AF patients. Catheter ablation of triggering electrical pulmonary veins activity or fibrotic areas defragmentation may be upgraded by miR therapy to prevent cardiac electrical and fibrotic remodeling after AF ablation.
心房颤动(AF)是普通人群中最常见的心律失常,其死亡率和发病率呈上升趋势。电生理和结构异常促进异常冲动的形成和传播,导致了这种疾病。AF导管消融与相当比例的无反应患者有关。微小RNA(miRs)已被用作AF纤维化和电改变的生物标志物。miRs可区分消融治疗的反应者患者。选择性miR靶向治疗,如通过腺病毒转染上调和/或通过抗miR下调miR,可用于治疗AF患者。通过miR治疗可提升触发肺静脉电活动或纤维化区域碎裂的导管消融,以预防AF消融后心脏电和纤维化重塑。